Maplight Therapeutics (NASDAQ:MPLT) Director Acquires $77,694.54 in Stock

Maplight Therapeutics, Inc. (NASDAQ:MPLT) Director George Pavlov acquired 4,422 shares of the business’s stock in a transaction on Thursday, February 19th. The stock was acquired at an average cost of $17.57 per share, for a total transaction of $77,694.54. Following the transaction, the director owned 15,080 shares of the company’s stock, valued at approximately $264,955.60. The trade was a 41.49% increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

George Pavlov also recently made the following trade(s):

• On Friday, February 20th, George Pavlov bought 9,920 shares of Maplight Therapeutics stock. The shares were acquired at an average cost of $17.86 per share, with a total value of $177,171.20.
• On Wednesday, February 18th, George Pavlov purchased 10,658 shares of Maplight Therapeutics stock. The stock was bought at an average cost of $17.48 per share, for a total transaction of $186,301.84.

Maplight Therapeutics Trading Down 0.2%

MPLT traded down $0.04 during trading on Friday, hitting $17.88. 120,504 shares of the company traded hands, compared to its average volume of 184,868. Maplight Therapeutics, Inc. has a one year low of $12.24 and a one year high of $21.55. The firm’s fifty day moving average price is $17.93. The firm has a market capitalization of $811.27 million and a price-to-earnings ratio of -0.48.

Maplight Therapeutics (NASDAQ:MPLT) last released its earnings results on Thursday, December 4th. The company reported ($37.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.86) by ($35.32).

Analyst Upgrades and Downgrades

MPLT has been the subject of several recent research reports. Wall Street Zen raised Maplight Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, December 20th. Morgan Stanley started coverage on shares of Maplight Therapeutics in a research note on Friday, November 21st. They issued an “overweight” rating and a $34.00 target price for the company. Stifel Nicolaus initiated coverage on shares of Maplight Therapeutics in a research note on Friday, November 21st. They set a “buy” rating and a $28.00 price target on the stock. Jefferies Financial Group assumed coverage on shares of Maplight Therapeutics in a research note on Friday, November 21st. They issued a “buy” rating and a $32.00 price objective for the company. Finally, Zacks Research upgraded Maplight Therapeutics to a “hold” rating in a research report on Monday, November 24th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $31.00.

Institutional Trading of Maplight Therapeutics

Hedge funds have recently made changes to their positions in the stock. Strs Ohio purchased a new position in Maplight Therapeutics in the fourth quarter worth $53,000. Police & Firemen s Retirement System of New Jersey purchased a new stake in Maplight Therapeutics during the fourth quarter valued at about $70,000. New York State Common Retirement Fund bought a new stake in Maplight Therapeutics during the fourth quarter worth about $93,000. MetLife Investment Management LLC bought a new stake in Maplight Therapeutics during the fourth quarter worth about $172,000. Finally, Walleye Capital LLC purchased a new position in shares of Maplight Therapeutics in the 4th quarter worth about $205,000.

Maplight Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.